O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-10.39%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.91B
AUM Growth
+$5.91B
(-15%)
Cap. Flow
-$46.9M
Cap. Flow
% of AUM
-0.79%
Top 10 Holdings %
Top 10 Hldgs %
34.46%
Holding
169
New
32
Increased
33
Reduced
28
Closed
26
Top Buys
| 1 |
Arcutis Biotherapeutics
ARQT
|
$139M |
| 2 |
Biogen
BIIB
|
$132M |
| 3 |
Passage Bio
PASG
|
$110M |
| 4 |
Pfizer
PFE
|
$98.3M |
| 5 |
Gilead Sciences
GILD
|
$85.6M |
Top Sells
| 1 |
THOR
Synthorx, Inc. Common Stock
THOR
|
$372M |
| 2 |
ARQL
Arqule Inc
ARQL
|
$99.8M |
| 3 |
Danaher
DHR
|
$98.1M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$93.8M |
| 5 |
Tandem Diabetes Care
TNDM
|
$68M |
Sector Composition
| 1 | Healthcare | 97.58% |
| 2 | Financials | 1.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $370M | 6.22% | 3,287,400 -55,700 | -2% | -$6.27M |
|
|
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
| $212M | 3.55% | 9,614,280 | – | – |
|
3
Alector
ALEC
$238M
| $201M | 3.38% | 8,327,691 -2,660,253 | -24% | -$64.2M |
|
|
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
| $200M | 3.36% | 7,406,307 | – | – |
|
5
Merck
MRK
$210B
| $199M | 3.35% | 2,589,100 +635,000 | +32% | +$48.9M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $186M | 3.13% | 2,071,385 +408,800 | +25% | +$36.7M |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $175M | 2.95% | 737,400 -45,700 | -6% | -$10.9M |
|
|
PRVL
8
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $168M | 2.83% | 13,822,463 | – | – |
|
9
Iovance Biotherapeutics
IOVA
$807M
| $166M | 2.79% | 5,548,326 | – | – |
|
10
Boston Scientific
BSX
$156B
| $158M | 2.66% | 4,847,300 +172,500 | +4% | +$5.63M |
|
|
11
Biogen
BIIB
$19.4B
| $152M | 2.55% | 480,400 +415,900 | +645% | +$132M |
|
|
12
Arcutis Biotherapeutics
ARQT
$1.86B
| $139M | 2.34% | +4,673,850 | New | +$139M |
|
13
Bristol-Myers Squibb
BMY
$96B
| $138M | 2.32% | 2,474,800 +774,800 | +46% | +$43.2M |
|
|
TPTX
14
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $123M | 2.06% | 2,745,327 | – | – |
|
|
15
Gilead Sciences
GILD
$140B
| $110M | 1.85% | 1,471,100 +1,145,000 | +351% | +$85.6M |
|
|
16
Passage Bio
PASG
$22.7M
| $110M | 1.84% | +6,962,899 | New | +$110M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $109M | 1.84% | 1,423,300 +82,700 | +6% | +$6.36M |
|
18
89bio
ETNB
$1.34B
| $101M | 1.7% | 4,004,442 | – | – |
|
19
NextCure
NXTC
$13.5M
| $100M | 1.69% | 2,711,013 | – | – |
|
20
Neurocrine Biosciences
NBIX
$13.8B
| $100M | 1.68% | 1,155,015 +219,045 | +23% | +$19M |
|
21
Natera
NTRA
$23.1B
| $99.9M | 1.68% | 3,347,000 +906,387 | +37% | +$27.1M |
|
|
22
Pfizer
PFE
$141B
| $98.3M | 1.65% | +3,012,100 | New | +$98.3M |
|
23
DexCom
DXCM
$29.5B
| $91M | 1.53% | 338,000 +103,100 | +44% | +$27.8M |
|
24
eHealth
EHTH
$118M
| $89.9M | 1.51% | 638,558 -473,356 | -43% | -$66.7M |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $88.3M | 1.48% | 902,449 +136,400 | +18% | +$13.3M |
|